Pliant Therapeutics (NASDAQ:PLRX) Price Target Lowered to $50.00 at Royal Bank of Canada

Pliant Therapeutics (NASDAQ:PLRX – Free Report) had its target price reduced by Royal Bank of Canada from $53.00 to $50.00 in a research report report published on Wednesday morning, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the stock. PLRX has been the subject of a number of other research reports. […]

Related Keywords

United States ,China ,Canada ,Mike Ouimette ,Bernard Coulie ,Wells Fargo Company ,China Universal Asset Management Co ,Securities Exchange Commission ,Royal Bank ,Quest Partners ,Pliant Therapeutics Inc ,Acadian Asset Management ,Us Bancorp ,Needham Company ,Pliant Therapeutics ,Free Report ,General Counsel Mike Ouimette ,Exchange Commission ,Universal Asset Management ,Asset Management ,Get Free Report ,Pliant Therapeutics Daily ,Nasdaq Plrx ,Plrx ,Medical ,Lower Price Target ,Royal Bank Of Canada ,